Concomitant CC and E2 Versus CC Alone in Ovulation Induction
Primary Purpose
Infertility, Anovulation
Status
Unknown status
Phase
Phase 4
Locations
Egypt
Study Type
Interventional
Intervention
Clomiphene citrate and Estradiol
Clomiphene citrate and Placebo
Sponsored by
About this trial
This is an interventional treatment trial for Infertility focused on measuring Clomiphene citrate, Estradiol, Endometrial thickness
Eligibility Criteria
Inclusion Criteria:
- Infertile women with eugonadotrophic anovulation/oligoovulation.
- Unexplained infertility.
Exclusion Criteria:
- Age < 20 or > 35 years.
- Body mass index (BMI) < 18.5 kg/m2 or > 25 kg/m2.
- Presence of any infertility factor other than anovulation/oligoovulation.
- Previous history of ovarian surgery or surgical removal of one ovary.
- Previous exposure to cytotoxic drugs or pelvic irradiation.
- Metabolic or hormonal abnormalities.
Sites / Locations
- Obstetrics and Gynecology Department in Mansoura University HospitalRecruiting
- Private practice settingsRecruiting
- Private practice settingsRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
Clomiphene citrate-Estradiol group
Clomiphene citrate group
Arm Description
Women will receive clomiphene citrate and estradiol
Women will receive clomiphene citrate and placebo
Outcomes
Primary Outcome Measures
Clinical pregnancy rate
Number of clinical pregnancies (defined as presence of at least one intrauterine gestational sac with fetal pole and cardiac activity on TVS scan at 6-8 weeks gestational age) divided by the number of women
Secondary Outcome Measures
Endometrial thickness on day of HCG administration
Endometrial thickness by TVS on day of HCG administration
Full Information
NCT ID
NCT02186782
First Posted
June 28, 2014
Last Updated
March 21, 2017
Sponsor
Maher elesawi kamel elesawi
1. Study Identification
Unique Protocol Identification Number
NCT02186782
Brief Title
Concomitant CC and E2 Versus CC Alone in Ovulation Induction
Official Title
Concomitant Clomiphene Citrate and Estradiol Versus Clomiphene Citrate Alone in Ovulation Induction: a Randomized Controlled Trial
Study Type
Interventional
2. Study Status
Record Verification Date
March 2017
Overall Recruitment Status
Unknown status
Study Start Date
June 2014 (undefined)
Primary Completion Date
July 2018 (Anticipated)
Study Completion Date
August 2018 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Maher elesawi kamel elesawi
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to evaluate the effect of concomitant administration of estradiol during use of clomiphene citrate (CC) for induction of ovulation in infertile women.
Detailed Description
Women will be randomly divided into two groups; CC-E2 group and CC group. Women in the CC-E2 group will receive CC (100 mg/day for 5 consecutive days from day 2 of cycle) and estradiol (2 mg/day for 5 consecutive days from day 2 of cycle). Women in the CC group will receive CC (100 mg/day for 5 consecutive days from day 2 of cycle) and placebo mimic estradiol (for 5 consecutive days from day 2 of cycle). Transvaginal sonography (TVS) scan will be performed regularly for monitoring of follicular growth (folliculometry); starting from day 10 of the stimulation cycle and repeated every 2-3 days. When there will be at least one follicle ≥ 18 mm in diameter, final oocyte maturation will be induced by intramuscular administration of 10000 IU of human chorionic gonadotropin (HCG) and timed intercourse will be advised. If there will be no follicle ≥ 12 mm by day 16 of the cycle, monitoring of follicular growth will be discontinued and the cycle will be presumed to be anovulatory. Ovulation will be documented by TVS scan one week after triggering of oocyte maturation and will be confirmed by assessing the midluteal serum progesterone level. Each woman will be subjected to ovarian stimulation for a maximum of 3 consecutive cycles except if she gets pregnant in the first or second cycle.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Infertility, Anovulation
Keywords
Clomiphene citrate, Estradiol, Endometrial thickness
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
600 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Clomiphene citrate-Estradiol group
Arm Type
Active Comparator
Arm Description
Women will receive clomiphene citrate and estradiol
Arm Title
Clomiphene citrate group
Arm Type
Active Comparator
Arm Description
Women will receive clomiphene citrate and placebo
Intervention Type
Drug
Intervention Name(s)
Clomiphene citrate and Estradiol
Other Intervention Name(s)
Clomid and Estradiol valerate
Intervention Description
Women will receive clomiphene citrate (100 mg/day for 5 consecutive days from day 2 of cycle) and estradiol (2 mg/day for 5 consecutive days from day 2 of cycle)
Intervention Type
Drug
Intervention Name(s)
Clomiphene citrate and Placebo
Other Intervention Name(s)
Clomid and Placebo
Intervention Description
Women will receive clomiphene citrate (100 mg/day for 5 consecutive days from day 2 of cycle) and placebo (for 5 consecutive days from day 2 of cycle)
Primary Outcome Measure Information:
Title
Clinical pregnancy rate
Description
Number of clinical pregnancies (defined as presence of at least one intrauterine gestational sac with fetal pole and cardiac activity on TVS scan at 6-8 weeks gestational age) divided by the number of women
Time Frame
6-8 weeks gestational age
Secondary Outcome Measure Information:
Title
Endometrial thickness on day of HCG administration
Description
Endometrial thickness by TVS on day of HCG administration
Time Frame
3 months
Other Pre-specified Outcome Measures:
Title
Ovulation rate
Description
Number of ovulatory cycles divided by the number of stimulation cycles
Time Frame
3 months
Title
Number of ovarian follicles ≥ 18 mm on day of HCG administration
Description
Number of ovarian follicles ≥ 18 mm by TVS on day of HCG administration
Time Frame
3 months
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
39 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Infertile women with eugonadotrophic anovulation/oligoovulation.
Unexplained infertility.
Exclusion Criteria:
Age < 20 or > 35 years.
Body mass index (BMI) < 18.5 kg/m2 or > 25 kg/m2.
Presence of any infertility factor other than anovulation/oligoovulation.
Previous history of ovarian surgery or surgical removal of one ovary.
Previous exposure to cytotoxic drugs or pelvic irradiation.
Metabolic or hormonal abnormalities.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Maher E Kamel Elesawi, Dr
Phone
+201016103662
Email
maherelesawi@yahoo.com
First Name & Middle Initial & Last Name or Official Title & Degree
Ahmed M Badawy, Prof
Phone
+201282848485
Email
ambadawy@yahoo.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ahmed M Badawy, Prof
Organizational Affiliation
Mansoura University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Maher E Kamel Elesawi, Dr
Organizational Affiliation
Mansoura University
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Mohamed S Abdelhafez, Dr
Organizational Affiliation
Mansoura University
Official's Role
Study Director
Facility Information:
Facility Name
Obstetrics and Gynecology Department in Mansoura University Hospital
City
Mansoura
State/Province
Dakahlia
ZIP/Postal Code
35111
Country
Egypt
Individual Site Status
Recruiting
Facility Name
Private practice settings
City
Mansoura
State/Province
Dakahlia
Country
Egypt
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ahmed M Badawy, Prof
Phone
+201282848485
Email
ambadawy@yahoo.com
First Name & Middle Initial & Last Name & Degree
Ahmed M Badaway, Prof
Facility Name
Private practice settings
City
Mit Ghamr
State/Province
Dakahlia
Country
Egypt
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Maher E Kamel Elesawi, Dr
Phone
+20104523494
Email
maherelesawi@yahoo.com
First Name & Middle Initial & Last Name & Degree
Maher E Kamel Elesawi, Dr
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Learn more about this trial
Concomitant CC and E2 Versus CC Alone in Ovulation Induction
We'll reach out to this number within 24 hrs